Univercells Technologies Launches scale-X™ nexo Bioreactor for Cost-Effective, Scalable Cell Culture

Univercells Technologies, a part of Donaldson, has introduced the scale-X™ nexo bioreactor, a miniaturized, fixed-bed bioreactor tailored to optimize cell culture in early-stage process development. With a compact 0.5 m² growth surface, the scale-X nexo simplifies process scaling, reducing time and costs for researchers and biopharma companies. This addition to the scale-X portfolio is ideal for those needing a highly efficient, cost-saving solution in cell and gene therapy or vaccine development.

scale-X nexo: Key Features for Advanced Bioprocessing

• Efficient Scaling Potential: Direct scalability to larger scale-X bioreactors, supporting growth from lab to commercial production.
• High-Density Cell Culture: Maintains consistent cell distribution, yielding high-density cultures critical for early development.
• Cost-Efficient Design: Offers up to 60% reduction in per-run costs compared to other entry-level bioreactors.
• Low-Volume, Low-Surface Area System: Reduces reagent and media requirements, minimizing resource use.
• Skaia™ Vision Software Compatibility: Estimates cell numbers without direct sampling, enhancing productivity.

The scale-X nexo bioreactor provides a high-performance solution that cuts costs and shortens timelines, making it an invaluable tool in efficient biomanufacturing.